GlassScriptPhysician profile
Mohamad Dabbagh
NPI 1902433402
$1,800.04
in general payments reported to CMS, 2019-2025
14 companies · $1,106 in 2025
The $1,106 reported for 2025 was more than what a typical Interventional Pain Medicine provider received nationally (typical 2025 total: $676).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $222 · 2023: $140 · 2024: $333 · 2025: $1,106.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $814 · Food and Beverage: $764.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $813.59 |
| Food and Beverage | $764.24 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Stryker Corporation | $789.94 | 2025 | Optablate |
| Spr Therapeutics, INC | $287.40 | 2025 | Sprint Pns System |
| Boston Scientific Corporation | $211.26 | 2024 | Intracept |
| Alkermes, INC. | $93.77 | 2022-2023 | Aristada, Lybalvi |
| Pfizer INC. | $81.55 | 2024 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $79.40 | 2022-2023 | |
| Otsuka America Pharmaceutical, INC. | $54.60 | 2022-2023 | Rexulti |
| Lundbeck LLC | $41.02 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $36.56 | 2023 | Trintellix |
| Idorsia Pharmaceuticals US INC | $35.77 | 2022-2023 | Quviviq |
| E.R. Squibb & Sons, L.L.C. | $28.29 | 2025 | Cobenfy |
| Avanir Pharmaceuticals, INC. | $20.70 | 2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $20.52 | 2024 | Relistor |
| Protega Pharmaceutials INC | $19.26 | 2024 | Roxybond |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mohamad Dabbagh listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.